Boyd L. Harrison
Sage Therapeutics (United States)(US)
Publications by Year
Research Areas
Neuroscience and Neuropharmacology Research, Receptor Mechanisms and Signaling, Cholinesterase and Neurodegenerative Diseases, Pharmacological Receptor Mechanisms and Effects, Synthesis and Biological Evaluation
Most-Cited Works
- → Begacestat (GSI-953): A Novel, Selective Thiophene Sulfonamide Inhibitor of Amyloid Precursor Protein γ-Secretase for the Treatment of Alzheimer’s Disease(2009)157 cited
- → WAY-163909 [(7 bR,10 aR)-1,2,3,4,8,9,10,10 a-Octahydro-7 bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Preclinical Antipsychotic-Like Activity(2006)145 cited
- → NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations(1991)127 cited
- → Neuroactive Steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1 H -pyrazol-1′-yl)-19-nor-5β-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric Acid) A Receptor(2017)120 cited
- → Discovery of Begacestat, a Notch-1-Sparing γ-Secretase Inhibitor for the Treatment of Alzheimer’s Disease(2008)109 cited
- → Acylguanidines as Small-Molecule β-Secretase Inhibitors(2006)